INVESTOR OVERVIEW

About Response Genetics, Inc.

Response Genetics, Inc. (“RGI”) (NASDAQ:RGDX) is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies which enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and is located in Los Angeles, California. For more information, please visit www.responsegenetics.com

RGDX (Common Stock)
Price3.08Change- 0.02
Volume950% Change0.65%
08/07/08 3:39 p.m. ETPricing delayed 20 minutes
Recent NewsMore >>
DateTitle 
08/07/08Response Genetics, Inc. to Release Second Quarter 2008 Financial ResultsPrinter Friendly Version
07/08/08Response Genetics, Inc. to Present at the Collins Stewart Fourth Annual Growth ConferencePrinter Friendly Version
06/16/08Response Genetics, Inc. to Hold Annual Meeting of Shareholders Tuesday, June 17, 2008 at 1:00 pm EDTPrinter Friendly Version
06/06/08StatementPrinter Friendly Version
Featured Report
There are currently no items available.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Response Genetics posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.